Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on:

Thursday 26 March 2026 at 14:00 (CET)

The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Further details on registration and participation are included in the enclosed meeting notice.

Novo Nordisk offers shareholders and others to follow the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the enclosed meeting notice for further information on the webcast.

BOARD OF DIRECTORS
All shareholder-elected Board members are up for election.

The Board of Directors proposes re-election of Lars Rebien Sørensen as Chair of the Board and re-election of Cees de Jong as Vice Chair. Moreover, the Board proposes re-election of Britt Meelby Jensen, Stephan Engels and Kasim Kutay. The Board proposes Helena Saxon, Jan van de Winkel and Ramona Sequeira as new members of the Board of Directors.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Company announcement No 12 / 2026